{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T16:47:11Z","timestamp":1769100431057,"version":"3.49.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.clml.2023.12.011","type":"journal-article","created":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T02:58:02Z","timestamp":1703818682000},"page":"e138-e141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Second Treatment-Free Remission Attempt in Patients with Chronic Myeloid Leukemia"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5034-3699","authenticated-orcid":false,"given":"Hiroshi","family":"Ureshino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuharu","family":"Kamachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.clml.2023.12.011_bib0001","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2023.12.011_bib0002","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.clml.2023.12.011_bib0003","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/ajh.26550","article-title":"Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors","volume":"97","author":"Haddad","year":"2022","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.clml.2023.12.011_bib0004","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet. Oncol."},{"issue":"3","key":"10.1016\/j.clml.2023.12.011_bib0005","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1016\/S2352-3026(19)30235-2","article-title":"Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial","volume":"7","author":"Kimura","year":"2020","journal-title":"Lancet. Haematol."},{"issue":"7","key":"10.1016\/j.clml.2023.12.011_bib0006","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/leu.2017.63","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study","volume":"31","author":"Hochhaus","year":"2017","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.clml.2023.12.011_bib0007","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1002\/cncr.30885","article-title":"Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia","volume":"123","author":"Legros","year":"2017","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.clml.2023.12.011_bib0008","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clml.2023.12.011_bib0009","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","article-title":"Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial","volume":"2","author":"Imagawa","year":"2015","journal-title":"Lancet. Haematol."},{"issue":"11","key":"10.1016\/j.clml.2023.12.011_bib0010","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.3324\/haematol.2018.194894","article-title":"Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan","volume":"103","author":"Takahashi","year":"2018","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.clml.2023.12.011_bib0011","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2023.12.011_bib0012","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.12.011_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2019.106273","article-title":"Role of cancer immunology in chronic myelogenous leukemia","volume":"88","author":"Ureshino","year":"2020","journal-title":"Leuk Res"},{"issue":"8","key":"10.1016\/j.clml.2023.12.011_bib0014","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3324\/haematol.2017.165001","article-title":"Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study","volume":"102","author":"Rea","year":"2017","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.clml.2023.12.011_bib0015","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.2009.25.5075","article-title":"Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia","volume":"28","author":"Burchert","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2023.12.011_bib0016","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/bjh.15858","article-title":"Sustained treatment-free remission in chronic myeloid leukaemia is associated with an increased frequency of innate CD8(+) T-cells","volume":"186","author":"Cayssials","year":"2019","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2023.12.011_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1084\/jem.20191009","article-title":"Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells","volume":"217","author":"Tanaka","year":"2020","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.clml.2023.12.011_bib0018","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/bjh.18796","article-title":"Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: results of the French Nilo post-STIM study","volume":"201","author":"Dulucq","year":"2023","journal-title":"Br J Haematol"},{"issue":"13","key":"10.1016\/j.clml.2023.12.011_bib0019","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1182\/bloodadvances.2020001772","article-title":"Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission","volume":"4","author":"Rousselot","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2023.12.011_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2022.100817","article-title":"Patient-specific molecular response dynamics can predict the possibility of relapse during the second treatment-free remission attempt in chronic myelogenous leukemia","volume":"32","author":"Kim","year":"2022","journal-title":"Neoplasia"},{"issue":"4","key":"10.1016\/j.clml.2023.12.011_bib0021","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/hon.2896","article-title":"Subsequent attempt tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia; a single institute experience","volume":"39","author":"Ureshino","year":"2021","journal-title":"Hematol Oncol"},{"issue":"21","key":"10.1016\/j.clml.2023.12.011_bib0022","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.2020009984","article-title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs","volume":"138","author":"R\u00e9a","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2023.12.011_bib0023","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41375-023-01829-9","article-title":"Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL","volume":"37","author":"Hochhaus","year":"2023","journal-title":"Leukemia"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023022000?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023022000?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T04:20:57Z","timestamp":1729052457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023022000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S2152265023022000"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.12.011","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second Treatment-Free Remission Attempt in Patients with Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}